Dr. David Jefferys, Eisai Medical Research - Qepler Summits And Conferences

Dr. David Jefferys

Senior Vice President
Eisai Medical Research
London, United Kingdom
Eisai Europe

Dr. Jefferys is currently the Senior Vice President for Global Regulatory, Patient Safety Healthcare Policy and Corporate Affairs, Eisai Europe and Chairman of the Eisai Global Regulatory Council and a member of the Safety Executive Committee and Global Safety Board.

He is a member of the Eisai Executive Committee, He is Chairman of the ABPI Regulatory Affairs Network and a member of the ABPI Innovation Board.

He chairs the Efpia Regulatory Expert Group and is a member of several EFPIA committees including the International Board and the Regulatory Strategy Committee.

He chairs the Efpia Dementia Special Interest Group Within IFPMA David is chairman of the Regulatory Science Committee and a member o IFPMA Council.

He joined Eisai in January 2005 on retirement from the UK Civil Service. Dr Jefferys qualified in medicine in 1975/76 from Guy’s Hospital Medical School.

He undertook House jobs at Guy’s and was a lecturer in medicine and on the registrar rotation in internal medicine diabetes and cardiology. He progressed to Senior registrar at St Thomas hospital and worked for a years as locum Consultant physician at Tunbridge Wells and Pembury hospitals.

After this career in clinical and academic medicines joined the UK Department of Health in 1985 to work on the review of medicines.

He rose to become Director of the Licensing Division and an executive director of Medicines Control Agency. During this time he served as the Principal Assessor to the Committee on the Safety of Medicines.

He was also a delegate to the CPMP from 1986 to 1994 and chaired the operations working party of the CPMP (now the CHMP).

From 1995 to 2000 he was the UK delegate on the CPMP (CHMP).

He chaired the Mutual Recognition Facilitation Group (MRFG) and the International Pharmaceutical Evaluation Reports Scheme Committee. He was a WHO adviser.

During this time Dr. Jefferys was involved in the foundation of ICH ( the International Committee on Harmonisation and worked on the E5 guideline on international clinical trials and the geriatric medicines guideline He was appointed to the CMR ( Centre for Medicines Research International Regulatory Board in 1992 becoming Chairman of the Advisory Board from 2000 to 2004. He remains a member of the CIRS Advisory Council.

In February 2000 he was appointed Chief Executive Director of the UK Medical Devices Agency of the Department of Health. During this time he served on the Medical Device Expert Group of the European Union and was vice chairman of the Global Harmonisation Task Force.

He was a member of the Healthcare Industry Task Force. On the creation of the MHRA he acted as joint chief executive until April 2004, when he transferred to become special advisor in advanced healthcare technology to the Department of Health and worked on secondment with the EMEA on benefit/risk evaluation.

Related Sessions:

2nd Annual Drug/Device
Combination Products Summit 2019

Get up to date with the regulatory and quality compliance strategies for combination product development.
  • 04 Dec 2019
  • Prague, CZ
  • Pharma
Day 2: Thursday, 05 December 2019
BLOCK: RISK MITIGATION STRATEGIES AND POST LAUNCH CONSIDREATIONS.
CASE STUDY: Post marketing and marketing surveillance for Combination Products.
  • The new requirements of Regulation 2017/745
  • PSURS and Market Surveillance Plans
  • Role of the QPPV
  • Handling Benefit-risk considerations and trend analyses
  • Avoid duplicative reporting
View Details